🔎 Trials Near Me

Utama › Mesotelioma › Tennessee

Kajian klinikal Mesotelioma di Tennessee

8 kajian untuk Mesotelioma sedang mencari peserta di lokasi di Tennessee.

Bandar di Tennessee

Teks kajian rasmi (Bahasa Inggeris)

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

  • Sarah Cannon Research Institute, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 28 Sep 2026 · NCT07277413

Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing

  • Vanderbilt University Medical Center, Nashville
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 25 Sep 2026 · NCT04981119

Study of ISM6331 in Participants With Advanced/Metastatic Mesothelioma or Other Advanced Solid Tumors

  • SCRI Oncology Partners, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 16 Sep 2026 · NCT06566079

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

  • Sarah Cannon Tennessee Oncology, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT05732831

Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

  • Vanderbilt - Ingram Cancer Center, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT05245500

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

  • Sarah Cannon Research Institute at Tennessee Oncology, Nashville
  • Tennessee Oncology, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 4 Ogo 2026 · NCT05579366

CT-95 in Advanced Cancers Associated With Mesothelin Expression

  • Context Investigational Site, Nashville
Mengambil pesertaFasa 1
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT06756035

A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression

  • Vanderbilt University Medical Center, Nashville
Mengambil pesertaFasa 1/2
Umur 18 ke atas · Semua jantina · Dikemas kini 12 Jun 2026 · NCT06051695

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.